{"id":"https://openalex.org/W2124378682","doi":"https://doi.org/10.1158/1535-7163.mct-13-0319-t","title":"Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations","display_name":"Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations","publication_year":2013,"publication_date":"2013-10-03","ids":{"openalex":"https://openalex.org/W2124378682","doi":"https://doi.org/10.1158/1535-7163.mct-13-0319-t","mag":"2124378682","pmid":"https://pubmed.ncbi.nlm.nih.gov/24092809","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4158732"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-13-0319-t","doi":"https://doi.org/10.1158/1535-7163.mct-13-0319-t","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-13-0319-t","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4158732","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064525438","display_name":"Prasanth Ganesan","orcid":"https://orcid.org/0000-0003-2762-6591","observed_orcids":["https://orcid.org/0000-0003-2762-6591"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Prasanth Ganesan","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071800834","display_name":"Filip Jank\u00fa","orcid":"https://orcid.org/0000-0002-8123-4065","observed_orcids":["https://orcid.org/0000-0002-8123-4065"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Filip Janku","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005436649","display_name":"Aung Naing","orcid":"https://orcid.org/0000-0002-4803-8513","observed_orcids":["https://orcid.org/0000-0002-4803-8513"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aung Naing","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David S. Hong","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044840107","display_name":"Apostolia Maria Tsimberidou","orcid":"https://orcid.org/0000-0003-2713-233X","observed_orcids":["https://orcid.org/0000-0003-2713-233X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Apostolia M. Tsimberidou","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069777765","display_name":"Gerald Steven Falchook","orcid":"https://orcid.org/0000-0001-9165-2191","observed_orcids":["https://orcid.org/0000-0001-9165-2191"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerald S. Falchook","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036211173","display_name":"Jennifer J. Wheler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer J. Wheler","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026538331","display_name":"Sarina Anne Piha-Paul","orcid":"https://orcid.org/0000-0001-9455-1660","observed_orcids":["https://orcid.org/0000-0001-9455-1660"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarina A. Piha-Paul","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045197829","display_name":"Siqing Fu","orcid":"https://orcid.org/0000-0002-1933-0419","observed_orcids":["https://orcid.org/0000-0002-1933-0419"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Siqing Fu","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009720074","display_name":"Vanda M. T. Stepanek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vanda M. Stepanek","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. Jack Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Jack Lee","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073079562","display_name":"Rajyalakshmi Luthra","orcid":"https://orcid.org/0000-0002-7133-0221","observed_orcids":["https://orcid.org/0000-0002-7133-0221"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rajyalakshmi Luthra","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003827387","display_name":"Michael James Overman","orcid":"https://orcid.org/0000-0001-5377-135X","observed_orcids":["https://orcid.org/0000-0001-5377-135X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Overman","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006348751","display_name":"Scott Kopetz","orcid":"https://orcid.org/0000-0001-9647-3416","observed_orcids":["https://orcid.org/0000-0001-9647-3416"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"E. Scott Kopetz","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035371911","display_name":"Robert A. Wolff","orcid":"https://orcid.org/0000-0002-6614-1610","observed_orcids":["https://orcid.org/0000-0002-6614-1610"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert A. Wolff","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]},{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]},{"id":"https://openalex.org/I4390039236","display_name":"Moores Cancer Center","ror":"https://ror.org/01qkmtm61","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800935791","https://openalex.org/I36258959","https://openalex.org/I4390039236"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","Moores Cancer Center, The University of California San Diego, La Jolla, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations: Departments of 1Investigational Cancer Therapeutics (Phase I Clinical Trials Program), 2Biostatistics, 3Gastrointestinal Medical Oncology, and 4Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 5Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959"]},{"raw_affiliation_string":"Moores Cancer Center, The University of California San Diego, La Jolla, California","institution_ids":["https://openalex.org/I36258959","https://openalex.org/I4390039236"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5071800834"],"corresponding_institution_ids":["https://openalex.org/I1343551460","https://openalex.org/I36258959","https://openalex.org/I4390039236"],"apc_list":null,"apc_paid":null,"fwci":3.4314,"has_fulltext":false,"cited_by_count":47,"citation_normalized_percentile":{"value":0.93471187,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"12","issue":"12","first_page":"2857","last_page":"2863"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.4968000054359436,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.4968000054359436,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.4916999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pik3ca-mutation","display_name":"PIK3CA mutation","score":0.9430000185966492},{"id":"https://openalex.org/keywords/advanced-colorectal-cancer","display_name":"advanced colorectal cancer","score":0.9570000171661377},{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.7820000052452087},{"id":"https://openalex.org/keywords/braf-mutation","display_name":"BRAF mutation","score":0.9300000071525574},{"id":"https://openalex.org/keywords/mtorc1-inhibitors","display_name":"mTORC1 inhibitors","score":0.925000011920929},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/akt-inhibitors","display_name":"AKT inhibitors","score":0.996999979019165},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.8109999895095825},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8539999723434448},{"id":"https://openalex.org/keywords/heavily-pretreated-patients","display_name":"heavily pretreated patients","score":0.8090000152587891}],"concepts":[{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.846152126789093},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.8351352214813232},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.7241414189338684},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6711273193359375},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.5303158164024353},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5078826546669006},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5022239685058594},{"id":"https://openalex.org/C98490376","wikidata":"https://www.wikidata.org/wiki/Q14876060","display_name":"mTORC1","level":4,"score":0.5019915103912354},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4903693199157715},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.38380324840545654},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.21228128671646118},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.13928085565567017},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08995437622070312}],"mesh":[{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011518","descriptor_name":"Proto-Oncogene Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016283","descriptor_name":"Proto-Oncogene Proteins p21(ras)","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018631","descriptor_name":"ras Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019869","descriptor_name":"Phosphatidylinositol 3-Kinases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D051057","descriptor_name":"Proto-Oncogene Proteins c-akt","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058534","descriptor_name":"Class I Phosphatidylinositol 3-Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.mct-13-0319-t","doi":"https://doi.org/10.1158/1535-7163.mct-13-0319-t","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-13-0319-t","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:24092809","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24092809","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4158732","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4158732","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Mol Cancer Ther","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:4158732","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4158732","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Mol Cancer Ther","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8399999737739563}],"study_designs":[],"awards":[{"id":"https://openalex.org/G8204861448","display_name":"Phase I Studies of Targeted Anti-Cancer Therapies","funder_award_id":"U01CA062461","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G9000878657","display_name":"Cancer Center Support Grant","funder_award_id":"P30CA016672","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F4320337376","display_name":"NIH Clinical Center","ror":"https://ror.org/04vfsmv21"},{"id":"https://openalex.org/F4320337853","display_name":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy","ror":"https://ror.org/04pst9c38"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1542117945","https://openalex.org/W1965626427","https://openalex.org/W1977246223","https://openalex.org/W1978194521","https://openalex.org/W1981976406","https://openalex.org/W1993739082","https://openalex.org/W2009494242","https://openalex.org/W2015015957","https://openalex.org/W2028959752","https://openalex.org/W2038725811","https://openalex.org/W2065703106","https://openalex.org/W2068877535","https://openalex.org/W2070841378","https://openalex.org/W2088286383","https://openalex.org/W2090533706","https://openalex.org/W2095253562","https://openalex.org/W2103414735","https://openalex.org/W2103900813","https://openalex.org/W2104830962","https://openalex.org/W2106494998","https://openalex.org/W2106543129","https://openalex.org/W2112521802","https://openalex.org/W2118073504","https://openalex.org/W2126783165","https://openalex.org/W2129172946","https://openalex.org/W2134519717","https://openalex.org/W2135131549","https://openalex.org/W2138425716","https://openalex.org/W2139248078","https://openalex.org/W2139712038","https://openalex.org/W2149626936","https://openalex.org/W2153389462","https://openalex.org/W2161375781","https://openalex.org/W2166084034","https://openalex.org/W2166310356","https://openalex.org/W2167997534","https://openalex.org/W2262414037"],"related_works":["https://openalex.org/W2118073504","https://openalex.org/W2009494242","https://openalex.org/W2330036869","https://openalex.org/W1994520717","https://openalex.org/W1839975169","https://openalex.org/W2485860988","https://openalex.org/W1978194521","https://openalex.org/W4365452464","https://openalex.org/W2054536628","https://openalex.org/W4415908237"],"abstract_inverted_index":{"Target-matched":[0],"treatment":[1],"with":[2,8,12,21,38,62,75,89,96,170,177,205,221],"PI3K/AKT/mTOR":[3,42,99,178,212],"pathway":[4,100,179],"inhibitors":[5,101,113,118,180,213],"in":[6,168,201],"patients":[7,20,46,74,88,169,204],"diverse":[9],"advanced":[10,207],"cancers":[11],"PIK3CA":[13,51,63,77,90,174,217],"mutations":[14,52,64,72,175,218],"have":[15,214],"shown":[16],"promise.":[17],"Tumors":[18],"from":[19,155],"colorectal":[22,171,208],"cancer":[23,172],"were":[24,34,56,94],"analyzed":[25],"for":[26,58,227],"PIK3CA,":[27],"KRAS,":[28],"and":[29,53,134],"BRAF":[30],"mutations.":[31,60],"PIK3CA-mutated":[32],"tumors":[33],"treated,":[35],"whenever":[36],"feasible,":[37],"agents":[39],"targeting":[40],"the":[41],"pathway.":[43],"Of":[44,86],"194":[45],"analyzed,":[47],"31":[48,87],"(16%)":[49],"had":[50,65,127,143],"189":[54],"(97%)":[55],"assessed":[57],"KRAS":[59,71,223],"Patients":[61],"a":[66,128,156],"higher":[67],"prevalence":[68],"of":[69,108,162],"simultaneous":[70,222],"than":[73],"wild-type":[76],"(71%,":[78],"22/31":[79],"vs.":[80],"43%,":[81],"68/158;":[82],"P":[83],"=":[84,182],"0.006).":[85],"mutations,":[91,224],"17":[92],"(55%)":[93],"treated":[95,176],"protocols":[97,210],"containing":[98],"[median":[102],"age,":[103],"57":[104],"years;":[105],"median":[106],"number":[107],"prior":[109],"therapies,":[110],"4;":[111],"mTORC1":[112],"(11),":[114],"phosphoinositide":[115],"3-kinase":[116],"(PI3K)":[117],"(5),":[119],"or":[120,130,148],"an":[121],"AKT":[122],"inhibitor":[123],"(1)].":[124],"None":[125],"(0/17)":[126],"partial":[129],"complete":[131],"response":[132],"(PR/CR)":[133],"only":[135],"1":[136],"[6%,":[137],"95%":[138,165],"confidence":[139],"interval":[140],"(CI),":[141],"0.01-0.27]":[142],"stable":[144,157],"disease":[145,158],"6":[146],"months":[147,189],"more,":[149],"which":[150],"was":[151,187],"not":[152],"significantly":[153],"different":[154],"\u22656":[159],"month/PR/CR":[160],"rate":[161],"16%":[163],"(11/67;":[164],"CI,":[166,191],"0.09-0.27)":[167],"without":[173],"(P":[181],"0.44).":[183],"Median":[184],"progression-free":[185],"survival":[186],"1.9":[188],"(95%":[190],"1.5-2.3).":[192],"In":[193],"conclusion,":[194],"our":[195],"data":[196],"provide":[197],"preliminary":[198],"evidence":[199],"that":[200],"heavily":[202],"pretreated":[203],"PIK3CA-mutant":[206],"cancer,":[209],"incorporating":[211],"minimal":[215],"activity.":[216],"are":[219],"associated":[220],"possibly":[225],"accounting":[226],"therapeutic":[228],"resistance.":[229]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":9}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}